Current Treatment and Challenge of Coloanal Disorders

Dear Colleagues,

Amid a flood of information, treatment options for coloanal disorders are growing rapidly. For inflammatory bowel disease (IBD), development of various biologics such as infliximab, adalimumab, and certolizumab pegol, as well as immunomodulators such as azathioprine and 6-Mercaptopurine, has led to improvement in patients’ drug compliance and the prognosis for IBD. As for surgical treatment of colon/rectal diseases, with the rapid development of minimally invasive surgical techniques, particularly for cancer, options for surgical treatment have become diversified including the recent robotic surgeries, thus improving the quality of life of the patients. In particular, the introduction and advancement of robotic surgery have shown oncological results comparable to those of laparoscopic operation, taking into account not only the quality of life of the patients but also the ergonomics of the operator.

Despite the accumulation of such diverse medical knowledge, more medical papers are still needed to establish a global guideline that can be applied to all patients regardless of nationality or race.

Through this Issue, we intend to deal with the contents of coloanal disorder and focus on places with the latest medical opinions covering not only diseases such as IBD but also colon/rectal diseases, including cancer and anal diseases.

Prof. Dr. Seong-taek Oh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.